Home / Going-concern warnings / Vivos Therapeutics, Inc.
Filed 2026-04-15 路 Form 10-K 路 Accession 0001493152-26-016854 nano
Price before filing: $1.35 (2026-04-14 close, split/dividend-adjusted)
Market cap at flag: $21.5M (2026-04-15) 路 Latest: $2.3M (2026-10-16)
| Window | VVOS | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -52.5% | +6.4% | -59.0% | 2026-05-15 |
| 90 days | -69.7% | +8.5% | -78.2% | 2026-07-14 |
| 180 days | -89.3% | +12.6% | -101.9% | 2026-10-12 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: Baker Tilly US, LLP
Source: independent auditor report in Form 10-K (period 2025-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.